The first bioactive wound dressing - exploiting the unique wound healing and antimicrobial properties of human collagen VI

Project Information

WOUNDCOM

Grant agreement ID: 947034

DOI

10.3030/947034

Project terminated on 30 September 2024

EC signature date 24 April 2020

Start date 1 May 2020

End date 31 December 2025

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 596 551,25

EU contribution

€ 2 514 575,00

Coordinated by

COLZYX AB
Sweden

Periodic Reporting for period 2 - WOUNDCOM (The first bioactive wound dressing - exploiting the unique wound healing and antimicrobial properties of human collagen VI)

Reporting period: 2021-05-01 to 2025-12-31

Summary of the context and overall objectives of the project

Colzyx addresses the problem of the wound management of non-healing (chronic) wounds.

Human collagen VI has unique wound healing and antimicrobial properties in the same molecule. Colzyx has identified, isolated and further developed key molecules from Human collagen VI and combined and optimised these to create a first-in-category bioactive product for wound management.

The product, WOUNDCOM, not only successfully manipulates the wound environment to facilitate healing but also forms an antibacterial barrier. WOUNDCOM caters to the large portion of previously unhealable wounds, accelerating the wound healing process and, at the same time, combating bacterial infections, including multi-drug resistant bacterial infections.

The value for society is healing of chronic wounds that will improve patient´s quality of life as well as providing health economic benefits.

The overall objectives of the project include:
- Developing and manufacture the clinical trial material according to quality and regulatory requirements for the clinical studies
- Determining WOUNDCOM wound healing performance in the treatment of chronic venous leg ulcers through the clinical trial
- Bringing the product to commercial readiness by completing the clinical validation study and obtaining CE-marking of the product.
- Building the trust in the product among potential partners and investors by validating efficacy & safety.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

In terms of the project management, the work proceeded as planned, with regular meetings with partners and clinicians. In relation to WOUNDCOM development, WOUNDCOM was developed according to the regulatory requirements and according to plan. The project was prematurely ended due to unforeseen requirements from the German authority BfArM. Colzyx has engaged in presentation of WOUNDCOM on both business and scientific events during the project.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The available wound care options can manipulate one or multiple aspects of the wound environment, but cannot form an antibacterial barrier and facilitate healing to a satisfactory level at the same time. Comparing to today’s wound dressings, WOUNDCOM will cater to the largest needs in wound management: fast wound healing process and combat of bacterial infection.

colzyx-logo.png